Could Paxlovid help treat long COVID? Here’s what we know – National |

Stories of two sufferers who discovered reduction from lengthy COVID after taking Pfizer Inc’s antiviral Paxlovid, together with a researcher who examined it on herself, present intriguing proof for medical trials to assist these affected by the debilitating situation, consultants and advocates say.

The researcher mentioned her power fatigue signs, which “felt like a truck hit me,” are gone after taking the two-drug oral remedy. Lengthy COVID is a looming well being disaster, estimated to have an effect on as much as 30 per cent of individuals contaminated with the coronavirus. It will possibly final for months, leaving many unable to work. Greater than 200 signs have been related to the situation, together with ache, fatigue, mind fog, respiratory issue and exhaustion after minimal quantities of bodily exercise.

Dr. Steven Deeks, a professor of medication on the College of California, San Francisco (USSF), and an professional in HIV remedy analysis, mentioned drug firms are inclined to low cost single-patient case research. However such cases have helped drive HIV remedy analysis, and Deeks thinks these Paxlovid circumstances may do the identical for lengthy COVID.

Story continues beneath commercial

“This supplies actually sturdy proof that we must be learning antiviral remedy on this context as quickly as attainable,” mentioned Deeks, including that he has heard of one more anecdotal case at UCSF by which an extended COVID affected person’s signs cleared after taking Paxlovid.

Learn extra:

Paxlovid ‘inaccessible’ to many patients in Canada. Here’s why that needs to change

Scientists warning that these circumstances are “hypothesis-generating solely” and never proof that the drug induced reduction of lingering signs. However they lend help to a number one concept that lengthy COVID could also be attributable to the virus persisting in components of the physique for months, affecting sufferers’ every day lives lengthy after acute signs disappear.

The perfect proof to date comes from a Nationwide Institutes of Well being (NIH) examine, at the moment beneath peer evaluation, by which researchers performed autopsies in 44 individuals who died of COVID-19 or one other trigger however have been contaminated with COVID. They discovered widespread an infection all through the physique, together with within the mind, that may final greater than seven months past the onset of signs.

Paxlovid, which mixes a brand new Pfizer tablet with the outdated antiviral ritonavir, is at the moment licensed to be used within the first days of a COVID an infection to forestall extreme illness in high-risk sufferers.

Pfizer spokesman Equipment Longley mentioned the corporate doesn’t have any lengthy COVID research underway and didn’t touch upon whether or not it could contemplate them.

Story continues beneath commercial

The drugmaker has two massive medical trials testing whether or not Paxlovid can forestall preliminary COVID an infection. That “could present us with related knowledge to assist inform future research,” Longley

Sufferers who’ve been struggling for months are rising pissed off with the dearth of pharmaceutical analysis for his or her situation.

There are at the moment fewer than 20 medical trials led by particular person researchers or small drugmakers testing therapies for lengthy COVID, solely a handful of which have moved past early phases, a Reuters evaluation discovered.

Diana Berrent, founding father of grassroots COVID advocacy group Survivor Corps, has been lobbying the Biden Administration to fund massive lengthy COVID medical trials.

“We shouldn’t be doing our analysis primarily based on anecdotal stories,” she mentioned. “That’s not adequate.”

Click to play video: 'Select high-risk Ontarians now eligible for COVID-19 anti-viral treatment'

Choose high-risk Ontarians now eligible for COVID-19 anti-viral therapy

Choose high-risk Ontarians now eligible for COVID-19 anti-viral therapy

In one of many case stories, revealed as a preprint forward of peer evaluation, a beforehand wholesome and vaccinated 47-year-old lady turned contaminated with COVID in the summertime of 2021. Most of her acute signs dissipated inside 48 hours, however she continued to have extreme fatigue, mind fog, exhaustion after train, insomnia, racing heartbeat and physique aches extreme sufficient that she
may not work.

Story continues beneath commercial

About six months after her preliminary an infection, she was reinfected, probably with COVID, and plenty of of her acute signs additionally returned. Her physician prescribed a five-day course of Paxlovid.

On day 3, she seen a speedy enchancment of lengthy COVID signs. “She’s again to regular,” mentioned Dr. Linda Geng, co-director of Stanford Well being Care’s lengthy COVID clinic and writer of the case report posted on Analysis Sq..

Within the second case, Lavanya Visvabharathy, 37, an immunologist working at Northwestern Drugs’s lengthy COVID clinic, was contaminated in December 2021. Her preliminary signs have been delicate, however she later skilled power fatigue, complications and sleep disturbances for 4 months after an infection. She additionally stored testing constructive on speedy antigen checks, an indication of viral persistence

Learn extra:

Lack of awareness over COVID-19 antiviral pill causing barrier to access: experts

Visvabharathy was conscious of the NIH examine and the Stanford case, and determined to strive Paxlovid to see if it may clear any lingering virus. Towards the top of the five-day course, her fatigue and insomnia had improved, and her complications have been much less frequent. Two weeks after therapy ended, her fatigue was gone.

“That’s 100% mounted,” she mentioned.

However to show Paxlovid supplies that type of reduction would require rigorously managed medical trials, Visvabharathy mentioned.

Story continues beneath commercial

Dr. Igor Koralnik, who heads Northwestern Drugs’s clinic targeted on the neurological results of lengthy COVID, famous the lengthy listing of widely-used drugs which are affected by ritonavir and mentioned Paxlovid “can’t be used willy nilly.”

“Paxlovid isn’t a benign medicine,” he mentioned. “There needs to be research.”

(Reporting by Julie Steenhuysen Enhancing by Michele Gershberg and Invoice Berkrot)

Leave a Comment